Learn about ovarian cancer treatment and research at virtual patient education event

May 26, 2022 Providence Cancer Institute of Oregon

Join Providence Cancer Institute of Oregon and Ovarian Cancer Alliance of Oregon and SW Washington for a free, virtual patient education event for ovarian cancer patients and their caregivers.

Christopher Darus, M.D., MS, gynecologic oncologist and medical director of Providence Gynecologic Oncology Program, will give an update on the latest developments in ovarian cancer diagnoses, treatments, research and clinical trials.

Virtual event details

June 29, 2022
7:00 p.m. to 8:15 p.m.

Register here

About Dr. Christopher Darus

Dr. Christopher Darus joined Providence Cancer Institute in October 2020 as medical director of Providence Gynecologic Oncology Program. He previously was director of gynecologic cancer research at Maine Medical Center in Portland, Maine.

Dr. Darus graduated from Wright State University School of Medicine in 2000 and completed his residency in Obstetrics and Gynecology at University of Colorado Health Sciences Center in 2004. Following his residency, he completed a fellowship in Gynecologic Oncology at the University of Virginia Health System in 2007. This rigorous training prepared Dr. Darus to offer advanced surgical and medical treatment techniques to his patients.

Dr. Darus has an acute understanding of the impact of a gynecologic cancer diagnosis and treatment on his patients and their families. He emphasizes the importance of treating the whole patient while utilizing the skills and strengths of the multidisciplinary team of providers at Providence Cancer Institute. His clinical interests include minimally invasive surgery, clinical trials and cancer genomics.

Dr. Darus is an avid cook and enjoys scuba diving and underwater photography. He lives in Portland with his wife and children.

Exceptional gynecologic cancer care

The Providence Gynecologic Oncology Program provides specialized care for women with suspected or known gynecologic malignancies and complex precancerous conditions. We offer care at two locations: Robert W. Franz Cancer Center at Providence Portland Medical Center and Providence St. Vincent Medical Center.

Through the program, patients have access to advanced treatments, such as robotic surgery, immunotherapy, and the latest research and clinical trials. Patients also have the convenience of receiving all their care in a single location. Learn more.

Related resources

Clinical trials: Leading breakthroughs in cancer research

Clinical trial aims to help premenopausal women at risk for ovarian cancer

Gynecologic oncology care now available at Providence Cancer Institute

Welcome to your journey for creating a healthier you

Learn about ovarian cancer treatment and research at virtual patient education event

Previous Article

Next Article

Learn about ovarian cancer treatment and research at virtual patient education event

Previous Article

Next Article

Other content in this Stream

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Learn about dysautonomia, its symptoms, and how it's connected to long COVID. Discover treatment options and expert insights at Providence.

A research collaboration between CORE, PSU researcher Dr. Roberta Hunte and the Healthy Birth Initiative (HBI), is studying the impact of a cross-sector partnership on Black maternal health outcomes.

A novel peptide vaccine against glioblastoma, a deadly brain tumor, is offering hope to some patients thanks to the work of an international effort including Providence's Santosh Kesari, MD, PhD.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

The procedure using the new TriClip to repair a leaky tricuspid valve was also a first in the Pacific Northwest.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A first-of-its-kind study on the efficacy and safety of weight loss medications in the real world is helping to provide clinicians with new is helping to provide clinicians with valuable new evidence.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

Over the next three years, this study seeks to identify the patterns of access and use of cancer services among high-risk patients to understand how to guide them toward quality care.

Providence researchers conducted over 2400 studies in 2023, according to the 2023 Providence Research Network Annual Report

Learn more about a clinical trial for men with metastatic prostate cancer.

In North Puget Sound, Providence Swedish has implemented solutions to address opioid overdoes, including participating in grant programs and research to discover addiction treatments that work.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.

The 2023 Providence Research Network annual report, released on Clinical Trials Day 2024, highlights the breadth and impact of research at Providence.